Pharmaceuticals, Biotechnology and Life Sciences
LEEDS, England–(BUSINESS WIRE)–4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today reported financial results for the full year ending December 31, 2021 and highlighted its key corporate objectives for 2022.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.
4D pharma has started with a multicentre Phase I/II double-blind, placebo-controlled study of MRx-4DP0004 in patients with poorly controlled asthma.
4D pharma’s study of Thetanix for treating Crohn’s disease has met primary objective, as it showed Thetanix was well tolerated with a good safety profile.
4D pharma showed that specific single bacterial strains from the human gut microbiota can serve as therapeutic inhibitors of the…
4D pharma has been cleared by the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Health Products Regulatory Authority…
A clinical stage biopharmaceutical company, 4D pharma, pioneering the development of Live Biotherapeutic Products, has made a deal with a subsidiary of…
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic…
4D Pharma’s Blautix, a single strain live biotherapeutic for the treatment of chronic abdomen disorder, Irritable Bowel Syndrome (IBS), has…
4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.